Category: Uncategorized

  Dr. Mark Williams, Chief Science Officer of Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW |OTCQB: AGNPF) speaks about two basic lines of evidence that suggest Ifenprodil should be active in treating COVID-19 patients. Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. …

Algernon Pharmaceuticals provides update on Phase 2B/3 study as they enroll 50th patient   Algernon Pharmaceutical (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with news the company has now enrolled a third of their patients in the Phase 2B/3 study of their repurposed drug Ifenprodil. Moreau discusses hitting that mark and also discusses the parameters of that study and whether they plan on releasing early data. …

Algernon Pharmaceuticals has big upside, says Mackie Research   Mackie Research launched coverage on Wednesday on drug developer Algernon Pharmaceuticals (Algernon Pharmaceuticals Stock Quote, Chart, News CSE:AGN) with a “Speculative Buy” rating, with analyst André Uddin saying the stock has a number of catalysts over the next few quarters. Vancouver-based Algernon is focused on repurposing for new indications in the US and European markets small molecule drugs already approved and genericized outside of those districts. Currently, Algernon has four repurposed drug candidates in its pipeline for indications including COVID-19, idiopathic pulmonary fibrosis (IPF), chronic cough, CKD, NASH and inflammatory bowel …

‘An effective treatment to reduce the severity and duration of a COVID infection’ – The Mercury   UTD study identifies multi-purpose use for drug Ifenprodil     A pharmaceutical company used a research study from UTD for affirming its potential treatment for COVID-19 recovery. COVID-19 causes inflammation in the lungs. Co-author of the research study in question — BBS professor Theodore Price — said this inflammatory response is initially caused by the immune system but can later be exacerbated by the nervous system. Neurogenic inflammation, which occurs when the nervous system and immune system start to interact, is driven by …

Pharmaceutical Firm Doses First Patient in Phase 2 IPF and Chronic Cough Trial Algernon Pharmaceuticals reported that the first patient has been dosed in the Phase 2 human study of Ifenprodil for treatment of idiopathic pulmonary fibrosis and chronic cough.   In a news release, Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW:FSE) announced that “the first patient has been dosed in its Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough clinical study of its re-purposed drug NP-120 (Ifenprodil).” The firm advised that this patient was enrolled and dosed at New Zealand’s Waikato Hospital. Algernon Pharmaceuticals noted that the objective of …

A pill that may lessen COVID-related lung damage. Miami will be first in U.S. to test it.   A Miami hospital will be the first in the country to test a possible COVID-19 treatment on humans this August. The research center at Westchester General Hospital in Coral Terrace is on its way to enroll patients to test Ifenprodil, a pill developed in the 1970s to treat blood circulation disorders that may alleviate some COVID-19 side-effects in the lungs. The drug, which was tested on a coronavirus patient overseas for the first time Wednesday, may reduce the severity and duration of …

Algernon Pharmaceuticals studies on Ifenprodil begins with patients on two fronts.   Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with news the company has started work with patients on two different application for the repurposed drug Ifenprodil. Moreau telling Proactive how the studies will be conducted for use on IPF and chronic cough and also for the second use for treatment with COVID-19.   …

Florida hospitals stretched to capacity by acute coronavirus outbreak Governor Ron DeSantis claims the situation is ‘stabilized’ but full ICU beds and overflowing emergency rooms tell a different story. A hospital in Fort Lauderdale, Florida on 17 July 2020. Photograph: Larry Marano/Rex/Shutterstock The emergency department at Jackson Memorial Hospital, wedged between Little Havana and the vibrant murals of Wynwood in Miami, has overflowed with Covid-19 patients for weeks. Coronavirus live news: France tells citizens to avoid Catalonia; Norway to quarantine travellers from Spain again Patients wait for beds in hallways and in the lounge. Some need oxygen minutes after arrival, …

Algernon Pharmaceuticals announces first site for U.S. clinical trial for Ifenprodil     Algernon Pharmaceuticals (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with news the company has announced a site for their multinational Phase 2b/3 human study of Ifenprodil for COVID-19. Moreau says that study will be conducted at the Westchester Research Center at Westchester General Hospital in Miami, Florida. The lead researcher will be Dr. Aimee Gonzalez. …

Algernon Pharmaceuticals begins screening patients for Phase 2 chronic cough and IPF study   Algernon Pharmaceuticals Inc. (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with news the company has begun screening patients in Australia for a Phase 2 idiopathic pulmonary fibrosis and chronic cough clinical study with their repurposed drug Ifenprodil. Moreau shared details about that study and he also takes a broader look at the drug Ifenprodil and the number of studies the company is undertaking to see it’s effectiveness in treating respiratory conditions. original link: https://ca.proactiveinvestors.com/companies/news/923942/algernon-pharmaceuticals-begins-screening-patients-for-phase-2-chronic-cough-and-ipf-study-923942.html   …